Brown Medical School
HIV 101: HIV Vaccine Candidates
By HEPP News Staff
October 2001
This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.
Adapted from Johnston M.I., Flores J. Progress in HIV Vaccine Development. Current Opinion in Pharmacology
. 2001:1(5):504-520. On the Web at www.niaid.nih.gov/daids/vaccine/pdf/pc1506.pdf. Additional information from Science Magazine
2001 293 (5537): 1973.
As drug-resistant HIV virus becomes more and more common, physicians will need alternative methods of treating the virus. One of the most promising of these methods is the development of a prophylactic or therapeutic vaccine. The following table provides information on vaccines currently in the development pipeline.
Vaccine Name | HIV Subtype Targeted | Producing Company | Status |
| gp120 | B/B, B/E | VaxGen | Ongoing phase III trials in the United States and Thailand |
| ALVAC-HIV | B, E | Aventis Pasteur | Ongoing phase II trials in the U.S., Haiti, Brazil, Trinidad (subtype B); Thailand (sub-type E); used alone or in combination with gp120 |
| ALVAC-HIV | A | Aventis Pasteur | Ready for Phase I trials in Uganda |
| Lipopeptides LP5, LP6 | B | ANRS: National Agency for AIDS Research, France | Ongoing phase I trials in France |
| Vaccinia TBC-3B | B | Therion | Ongoing phase I trials in the U.S. |
| DNA-HIV | B | Apolion | Completed phase I trials |
| DNA-HIV, MVA-HIV | A | University of Oxford | Ongoing phase I trials in the UK and Kenya |
| NYVAC-HIV | B | Aventis Pasteur | Ready for phase I in the U.S. |
| DNA-HIV, Adenovirus HIV | B | Merck | Ongoing phase I trials in the U.S. |
| VaxGen Canarypox with HIV gag, protease, and env +gp120 | B/E | U.S. Military, Royal Thai Govt., Mahidol U., Aventis Pasteur, VaxGen | Earliest phase III start date: Summer 2002, Thailand* |
| Canarypox with HIV env, gag, protease, pol, and nef, +gp120 | B/? | NIH HVTN, Aventis Pasteur, VaxGen | Earliest phase III start date: December 2002, U.S., Brazil, Haiti, Peru, Trinidad (Possible: Argentina, Dominican Republic, Honduras)* |
|
* Proposed AIDS vaccine efficacy trials (see "News Flashes").
Advertisementphase I trial: first stage trial, focusing on safety and toxicity, very small cohort.
phase II trial: second stage trial, measures efficacy of vaccine in small cohort.
phase III trial: last stage of experimental testing, pivotal trial measures efficacy on a larger scale.
gp120: recombinant HIV envelope protein.
ALVAC-HIV: a recombinant canarypox virus expressing multiple HIV genes.
MVA-HIV: modified vaccinia Ankara (an attenuated vaccinia vector) expressing multiple HIV genes.
NYVAC-HIV: an attenuated vaccinia vector expressing multiple HIV genes.
TBC-3B: an attenuated vaccinia vector expressing multiple HIV genes.
|
Back to the HEPP News October 2001 contents page.
This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.
This article was provided by
Brown Medical School.
It is a part of the publication HEPP News.
E-Mail
Printable Single-Page
Glossary
PDF
Share
